[go: up one dir, main page]

ATE373714T1 - Lps mit reduzierter toxizität von genetisch modifizierten gram-negativen bakterien - Google Patents

Lps mit reduzierter toxizität von genetisch modifizierten gram-negativen bakterien

Info

Publication number
ATE373714T1
ATE373714T1 AT98954832T AT98954832T ATE373714T1 AT E373714 T1 ATE373714 T1 AT E373714T1 AT 98954832 T AT98954832 T AT 98954832T AT 98954832 T AT98954832 T AT 98954832T AT E373714 T1 ATE373714 T1 AT E373714T1
Authority
AT
Austria
Prior art keywords
lps
molecule
acyl chains
recombinant
glucosamine
Prior art date
Application number
AT98954832T
Other languages
English (en)
Inventor
Der Ley Peter Van
Hendrik Hamstra
Liana Steeghs
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19866463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE373714(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Application granted granted Critical
Publication of ATE373714T1 publication Critical patent/ATE373714T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Purification Treatments By Anaerobic Or Anaerobic And Aerobic Bacteria Or Animals (AREA)
AT98954832T 1998-11-03 1998-11-03 Lps mit reduzierter toxizität von genetisch modifizierten gram-negativen bakterien ATE373714T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL1998/000633 WO2000026384A1 (en) 1998-11-03 1998-11-03 Lps with reduced toxicity from genetically modified gram negative bacteria

Publications (1)

Publication Number Publication Date
ATE373714T1 true ATE373714T1 (de) 2007-10-15

Family

ID=19866463

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98954832T ATE373714T1 (de) 1998-11-03 1998-11-03 Lps mit reduzierter toxizität von genetisch modifizierten gram-negativen bakterien

Country Status (12)

Country Link
US (1) US6482807B1 (de)
EP (2) EP1127137B2 (de)
JP (1) JP3595264B2 (de)
AT (1) ATE373714T1 (de)
AU (1) AU762369B2 (de)
CA (1) CA2348928C (de)
DE (1) DE69838460T3 (de)
DK (1) DK1127137T4 (de)
ES (1) ES2294821T5 (de)
NZ (1) NZ511438A (de)
PT (1) PT1127137E (de)
WO (1) WO2000026384A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
KR100829674B1 (ko) * 2000-05-19 2008-05-16 코릭사 코포레이션 단당류 또는 이당류계 화합물을 이용한 전염성 및 다른질병의 예방 및 치료 방법
KR20030024811A (ko) * 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
AU2002223970A1 (en) * 2000-10-06 2002-04-15 H. Henrich Paradies Kyberdrug as autovaccines with immune-regulating effects
US20030068324A1 (en) * 2001-04-06 2003-04-10 Jean-Michel Fournier Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid
WO2004014417A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
EP1654364A4 (de) * 2003-08-13 2008-02-13 Novartis Vaccines & Diagnostic Zuführung von immungene codierenden polynukleotiden an inakivierte wirtszellen
CN1997392B (zh) * 2004-05-11 2011-06-01 荷兰健康、福利与体育部部长代表的荷兰国 作为佐剂的脑膜炎奈瑟氏菌lgtB LOS
ES2493440T3 (es) * 2004-12-17 2014-09-11 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Desacilación de LPS en bacterias Gram negativas
BRPI0607374B8 (pt) 2005-01-27 2021-05-25 Childrens Hospital & Res Center At Oakland vacinas de vesículas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
EP2032160B2 (de) 2006-06-12 2013-04-03 GlaxoSmithKline Biologicals S.A. Impfstoff
ES2393682T3 (es) * 2007-03-26 2012-12-27 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vacunas mejoradas contra Bordotella pertussis basadas en mutantes de glicosiltransferasa LPS
EP2185576A4 (de) * 2007-08-02 2011-01-12 Childrens Hosp & Res Ct Oak Vesikelimpfstoffe auf fhbp- und lpxl1-basis für breitbandschutz gegen neisseria meningitidis-bedingte erkrankungen
CA2702871A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
NZ593674A (en) 2008-12-17 2013-03-28 Novartis Ag Meningococcal vaccines including hemoglobin receptor
SMT202000366T1 (it) 2009-03-24 2020-09-10 Glaxosmithkline Biologicals Sa Proteina legante fattore h di meningococco come adiuvante
US20120064103A1 (en) 2009-03-24 2012-03-15 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
CA2761924C (fr) 2009-05-14 2017-10-31 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6
AU2010247252A1 (en) 2009-05-14 2012-01-12 Sanofi Pasteur Method for admixing the lipopolysaccharide (LPS) of gram-negative bacteria
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
WO2011110634A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Vaccine composition
EP2547357A1 (de) 2010-03-18 2013-01-23 Novartis AG Adjuvierte impfstoffe für serogruppen-b-meningokokken
US20130066064A1 (en) * 2010-05-20 2013-03-14 Glaxosmithkline Biologicals S.A, Novel process
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
EP2707009A1 (de) 2011-05-12 2014-03-19 Novartis AG Antipyretika zur verbesserung der verträglichkeit von impfstoffen auf vesikelbasis
EP2729167B1 (de) 2011-07-07 2018-03-14 De Staat der Nederlanden, vert. door de Minister van VWS Verfahren zur reinigungsmittelfreien herstellung der aussenmembranvesikel eines gramnegativen bakteriums
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
ES2654613T3 (es) 2012-02-02 2018-02-14 Glaxosmithkline Biologicals Sa Promotores para una expresión aumentada de proteínas en meningococos
AU2013311702A1 (en) 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
EP2953620A1 (de) 2013-02-07 2015-12-16 GlaxoSmithKline Biologicals SA Pharmazeutische zusammensetzungen mit vesikeln
ES2828373T3 (es) 2013-06-04 2021-05-26 Aparin Petr Gennadievich Lipopolisacárido modificado (variantes) de bacterias endotóxicas, combinación de lipopolisacáridos modificados (variantes) y una vacuna (variantes), que los contiene, y una composición farmacéutica (variantes)
JP2018501322A (ja) * 2015-01-12 2018-01-18 チルドレンズ メディカル センター コーポレーション トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
BR112018015237A2 (pt) * 2016-01-28 2018-12-26 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport lps de neisseria hexa-acilado modificado
EP3263695A1 (de) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogene zusammensetzungen
DK4117790T3 (da) * 2020-03-13 2025-01-27 Hephaistos Pharma Detoksificerede lipopolysaccharider (lps), naturligt ikke-toksisk lps og anvendelser deraf
AU2021271805A1 (en) * 2020-05-14 2022-12-01 Zivo Bioscience, Inc. Use of TLR4 modulator in the treatment of coccidiosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
WO1997025061A1 (en) * 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria

Also Published As

Publication number Publication date
DE69838460T3 (de) 2014-04-30
PT1127137E (pt) 2007-12-28
CA2348928C (en) 2010-01-26
EP1127137A1 (de) 2001-08-29
WO2000026384A1 (en) 2000-05-11
JP3595264B2 (ja) 2004-12-02
EP1870468A2 (de) 2007-12-26
JP2002528558A (ja) 2002-09-03
US6482807B1 (en) 2002-11-19
NZ511438A (en) 2003-03-28
EP1127137B2 (de) 2013-12-25
CA2348928A1 (en) 2000-05-11
EP1127137B1 (de) 2007-09-19
DK1127137T4 (da) 2014-02-10
DE69838460D1 (de) 2007-10-31
DE69838460T2 (de) 2008-06-12
ES2294821T5 (es) 2014-03-05
EP1870468A3 (de) 2010-01-13
AU1178299A (en) 2000-05-22
ES2294821T3 (es) 2008-04-01
DK1127137T3 (da) 2008-01-02
AU762369B2 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
ATE373714T1 (de) Lps mit reduzierter toxizität von genetisch modifizierten gram-negativen bakterien
DE69319976D1 (de) 7-Substituierte-9-substituierte Glycylamido-6-Demethyl-6-Deoxytetracycline
PT618190E (pt) 9-¬glicil substituido)amido|-6-(substituido)-5-hidroxi-6-desoxitetraciclinas
EA200000048A1 (ru) ИНГИБИТОРЫ ФАКТОРА Ха, СОДЕРЖАЩИЕ ГРУППУ С НЕЙТРАЛЬНОЙ P1-СПЕЦИФИЧНОСТЬЮ
FI943084A0 (fi) Uusia sulfonyyliaminopyrimidiinejä
ITMI930366A0 (it) Addittivi superfluidificanti ad elevata conservazione della lavorabilita'
ATE215530T1 (de) 7-substituierte-8-substituierte-9-substituierte amino-7-demethyl-6-deoxy-tetracycline als antibiotische mittel
TW269678B (de)
EA199900598A1 (ru) Производные 1-арил- и пиридилпиразола с пестицидными свойствами
FI932103A0 (fi) Nya 4-arylpiperaziner och 4-arylpiperidiner
GR1000118B (el) Συνθεσις 1,2-διοξετανων & ενδιαμεσαι ουσιαι δι αυτην.
ATE75752T1 (de) Antibiotikum.
KR950701162A (ko) 카르테시안 멀티 캐리어 피드백(cartesian multicarrier feedback)
FI931079A0 (fi) Mikrobmotverkande karbapenemderivat, deras framstaellning och terapeutiska anvaendning
ES2125309T3 (es) Derivados de tiomarinol y procedimientos para su preparacion.
ES2052493T3 (es) Utilizacion de inhibidores de girasa para la descontaminacion de cultivos celulares infectados con micoplasma.
HU9602129D0 (en) Condensation and addition polymers with n,n'-bridged bis-tetramethylpiperidinyloxy groups
BR9407232A (pt) Compostos de tiocarbamoíla
DE69112642D1 (de) Glutaminhaltige lyophilisierte aminokarbonsäurenzusammensetzungen.
BR9106596A (pt) Processo para o tratamento ou profilaxia de uma infeccao associada com retrovirus,uso,composicao farmaceutica para o tratamento ou profilaxia de uma infeccao associada com retrovirus,e,composto
IT1251722B (it) Ammidi organiche fosforose adatte come stabilizzanti e composizioni polimeriche che le comprendono
NO963216L (no) Kondensasjons- og addisjonspolymerer med N,N'-brodannede bis-tetrametylpiperidinyloksygrupper
DE59914550D1 (de) Synthetisches nukleinsäure-partikel
ATE222262T1 (de) Antibiotisch wirksame stalobacine
IT1274024B (it) Derivati polimerici del benzopiran-2-one ad attivita' immunotropa, loro uso e composizioni farmaceutiche che li contengono

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1127137

Country of ref document: EP